Renal side effects of anti-VEGF therapy in man: a new test system.
Ostendorf
Tammo
T
Division of Nephrology, University Hospital Aachen, Pauwelsstr. 30, D-52057 Aachen, Germany. tostendorf@ukaachen.de
De Vriese
An S
AS
Floege
Jürgen
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068258:Bevacizumab; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D006579:Heterozygote; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008024:Ligands; D051379:Mice; D020033:Protein Isoforms; D017434:Protein Structure, Tertiary; D011507:Proteinuria / Q000209:etiology; D051381:Rats; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008024:Ligands; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab